Omeros Corporation (OMER)

NGM – Real vaqt narxi. Valyuta: USD

8.67

-2.05 (-19.12%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

8.65

-0.02 (-0.23%)

Bozordan keyin: Jun 26, 2026, 7:58 PM EDT

04.06.2026

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

14.05.2026

Omeros Q1 Earnings Call Highlights

Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.

14.05.2026

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

13.05.2026

Omeros Corporation Reports First Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of.

11.05.2026

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click.

27.04.2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

27.04.2026

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Videolar

No Data

There is no data to display

Press-relizlar

13.05.2026

Omeros Corporation Reports First Quarter 2026 Financial Results

16.04.2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. “For patients with TA-TMA, access to e.

31.03.2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $1.

21.03.2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp.

Omeros Corporation (OMER)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Omeros Corporation (OMER)

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Search stocks

Omeros Corporation (OMER)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Omeros Corporation (OMER)

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment